Skip to main content
Figure 5 | BMC Medicine

Figure 5

From: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy

Figure 5

Results of clopidogrel low-response (CLR) following therapy modification without prasugrel. The left section of the figure shows the prevalence in % (numbers) of clopidogrel responder and clopidogrel low responder (CLR). In the right section are the results after therapy modification according to the therapy algorithm for CLR. Treatment options used: clopidogrel responder (75 mg daily), high clopidogrel dose (150 mg daily), ticlopidine (250 mg twice daily).

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us